ArticleCurrent oncology (Toronto, Ont.)2026
Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Emmanuel Joran Boujeke, Aaron Catalan, Laurice Arayan, Alfred Patrick Mina, Christian Edward James-McDonald, Rasna Gupta, Swati Kulkarni, Abdullah Nasser, Deepro Chowdhury, Muriel Brackstone and 2 more
Abstract read
In one paragraphArticle in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Emmanuel Joran BoujekeSchulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.
Laurice ArayanSchulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.
Alfred Patrick MinaSchulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.
Christian Edward James-McDonaldSchulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.
Rasna GuptaSchulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.
Swati KulkarniSchulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.
Abdullah NasserSchulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.ORCID 0000-0002-1302-2861 Deepro ChowdhurySchulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.
Muriel BrackstoneSchulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.ORCID 0000-0002-7741-2199 John MathewsSchulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.
Caroline HammSchulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.ORCID 0000-0003-1326-2088 Funding
Bristol Myers Squibb None
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalTriple Negative Breast NeoplasmsAdultAgedFemaleHumansMiddle AgedNeoplasm StagingPathologic Complete ResponseRetrospective StudiesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumabbreast cancerimmunotherapypembrolizumab
Identifiers
PMID42782860
PMCPMC13605040
What OpenQuestion holds
Textmetadata
Read underepoch 390